1 false false false false false false false false false false true false false false false false false No description of principal activity 2023-03-01 Sage Accounts Production Advanced 2023 - FRS102_2023 xbrli:pure xbrli:shares iso4217:GBP 07955184 2023-03-01 2024-02-29 07955184 2024-02-29 07955184 2023-02-28 07955184 2022-03-01 2023-02-28 07955184 2023-02-28 07955184 2022-02-28 07955184 bus:Director2 2023-03-01 2024-02-29 07955184 core:WithinOneYear 2024-02-29 07955184 core:WithinOneYear 2023-02-28 07955184 core:ShareCapital 2024-02-29 07955184 core:ShareCapital 2023-02-28 07955184 core:RetainedEarningsAccumulatedLosses 2024-02-29 07955184 core:RetainedEarningsAccumulatedLosses 2023-02-28 07955184 bus:Director2 2023-02-28 07955184 bus:Director2 2024-02-29 07955184 bus:Director2 2022-02-28 07955184 bus:Director2 2023-02-28 07955184 bus:Director2 2022-03-01 2023-02-28 07955184 bus:SmallEntities 2023-03-01 2024-02-29 07955184 bus:AuditExemptWithAccountantsReport 2023-03-01 2024-02-29 07955184 bus:SmallCompaniesRegimeForAccounts 2023-03-01 2024-02-29 07955184 bus:PrivateLimitedCompanyLtd 2023-03-01 2024-02-29 07955184 bus:FullAccounts 2023-03-01 2024-02-29
COMPANY REGISTRATION NUMBER: 07955184
SKIN ASSOCIATES LIMITED
FILLETED UNAUDITED FINANCIAL STATEMENTS
29 February 2024
SKIN ASSOCIATES LIMITED
STATEMENT OF FINANCIAL POSITION
29 February 2024
2024
2023
Note
£
£
£
Fixed assets
Tangible assets
5
6,693
8,924
Current assets
Stocks
1,963
1,792
Debtors
6
69,261
61,324
Cash at bank and in hand
51,060
57,191
----------
----------
122,284
120,307
Creditors: amounts falling due within one year
7
126,954
127,850
----------
----------
Net current liabilities
4,670
7,543
-------
-------
Total assets less current liabilities
2,023
1,381
Provisions
Taxation including deferred tax
99
-------
-------
Net assets
2,023
1,282
-------
-------
SKIN ASSOCIATES LIMITED
STATEMENT OF FINANCIAL POSITION (continued)
29 February 2024
2024
2023
Note
£
£
£
Capital and reserves
Called up share capital
100
100
Profit and loss account
1,923
1,182
-------
-------
Shareholders funds
2,023
1,282
-------
-------
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of income and retained earnings has not been delivered.
For the year ending 29 February 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors' responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .
These financial statements were approved by the board of directors and authorised for issue on 17 October 2024 , and are signed on behalf of the board by:
Mrs F C Dilazzaro
Director
Company registration number: 07955184
SKIN ASSOCIATES LIMITED
NOTES TO THE FINANCIAL STATEMENTS
YEAR ENDED 29 FEBRUARY 2024
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is 168 Church Road, Hove, East Sussex, BN3 2DL.
2. Statement of compliance
These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Going concern
The financial statements have been prepared under the going concern basis which assumes that the company will continue in operational existence for the foreseeable future. The validity of this assumption depends upon the continuing support of the company's connected companies and directors.
If the company were unable to continue in operational existence for the foreseeable future, adjustments would have to be made to reduce the balance sheet values of the assets to their recoverable amounts and to provide for further liabilities that might arise. The directors believe that it is appropriate for the financial statements to be prepared on the going concern basis.
Judgements and key sources of estimation uncertainty
The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.
Revenue recognition
Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax. Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.
Income tax
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.
Tangible assets
Tangible assets are initially recorded at cost, and subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in equity, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation, is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in equity in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in equity in respect of that asset, the excess shall be recognised in profit or loss.
Depreciation
Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:
Equipment
-
25% reducing balance
Impairment of fixed assets
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. For the purposes of impairment testing, when it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that largely independent of the cash inflows from other assets or groups of assets. For impairment testing of goodwill, the goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the company are assigned to those units.
Stocks
Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost includes all costs of purchase, costs of conversion and other costs incurred in bringing the stock to its present location and condition.
Financial instruments
Financial instruments are classified and accounted for, according to the substance of the contractual arrangement, as either financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.
4. Employee numbers
The average number of persons employed by the company during the year amounted to 1 (2023: 1 ).
5. Tangible assets
Equipment
Total
£
£
Cost
At 1 March 2023 and 29 February 2024
96,708
96,708
---------
---------
Depreciation
At 1 March 2023
87,784
87,784
Charge for the year
2,231
2,231
---------
---------
At 29 February 2024
90,015
90,015
---------
---------
Carrying amount
At 29 February 2024
6,693
6,693
---------
---------
At 28 February 2023
8,924
8,924
---------
---------
6. Debtors
2024
2023
£
£
Amounts owed by group undertakings and undertakings in which the company has a participating interest
69,224
60,724
Other debtors
37
600
---------
---------
69,261
61,324
---------
---------
7. Creditors: amounts falling due within one year
2024
2023
£
£
Amounts owed to group undertakings and undertakings in which the company has a participating interest
124,462
124,463
Corporation tax
698
373
Other creditors
1,794
3,014
----------
----------
126,954
127,850
----------
----------
8. Directors' advances, credits and guarantees
During the year the directors entered into the following advances and credits with the company:
2024
Balance brought forward
Advances/ (credits) to the directors
Balance outstanding
£
£
£
Mrs F C Dilazzaro
( 134)
20
( 114)
----
----
----
2023
Balance brought forward
Advances/ (credits) to the directors
Balance outstanding
£
£
£
Mrs F C Dilazzaro
( 145)
11
( 134)
----
----
----
9. Related party transactions
The company was under the control of Skin Associates (Holdings) Limited throughout the current year. As at 29th February 2024 the company was owed £69,224 (2023: £60,724) from Skin Associates (Holdings) Limited. Mr F Dilazzaro, Mrs F Dilazzaro are directors of Skin Associates (Holdings) Limited. As at 29th February 2024 the company owed £124,461(2023: £124,461) to Skin Associates (Medical) Limited. Mr F Dilazzaro, Mrs F Dilazzaro are directors of Skin Associates (Medical) Limited.